View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Innovent Biologics (1801 HK): 1H25: Achieves robust earnings; enters a...

Innovent’s 1H25 revenue surged 50.6% yoy to Rmb6.0b, far exceeding market estimates. Adjusted earnings reached Rmb1.2b in 1H25. With a new wave of product launches driving growth, Innovent has embarked on a dual-engine growth strategy in oncology and general biomedicines. Committed to developing pioneering pipeline assets for the global market, Innovent is poised to become a significant player in the global biopharma market. Maintain BUY with a higher target price of HK$120.00.

Carol Dou Xiao Qin ... (+15)
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Colin Lee
  • Damon Shen
  • Ejann Hiew
  • Gigi Cheuk
  • Greater China Research Team
  • Jieqi Liu
  • Johnny Yum Chung Man
  • Kate Luang
  • Kenny Yong Hui Lim
  • Shirley Wang Xueyi
  • Stella Guo Yuting
  • Sunny Chen
  • Ziv Ang Sze Champ

Greater China Daily: Thursday, August 28, 2025

KEY HIGHLIGHTS Results Anhui Conch Cement (914 HK/BUY/HK$24.46/Target: HK$28.90) Anhui Conch Cement reported 1H25 earnings of Rmb4,367.9m (+31.3% yoy), representing 42.5% of our full-year estimates, slightly above expectations. Gross margin for self-produced products rose to 28.9% (+5.8ppt yoy). Cement ASP edged up 1.5% yoy, while unit production cost fell 7.1% yoy, mainly on a 13.8% drop in fuel and power costs. Cement and clinker sales volume was broadly stable at 126mt (-0.4% yoy), outperfo...

Adrian Loh Tzum Yung ... (+25)
  • Adrian Loh Tzum Yung
  • Arsit Pamaranont
  • Carol Dou Xiao Qin
  • Chong Lee Len
  • Claire Wang Kelai
  • Colin Lee
  • Damon Shen
  • Ejann Hiew
  • Gigi Cheuk
  • Jack Goh Tooan Orng
  • Jack Lai Yuan Khai
  • Jieqi Liu
  • Jo Yee Ng
  • Johnny Yum Chung Man
  • Julia Pan Mengyao
  • Kate Luang
  • Keith Wee Teck Keong
  • Kenny Yong Hui Lim
  • Ming San Soong
  • Shirley Wang Xueyi
  • Stella Guo Yuting
  • Sunny Chen
  • Tanapon Cholkadidamrongkul
  • Willinoy Sitorus
  • Ziv Ang Sze Champ

Regional Morning Meeting Notes: Thursday, August 28, 2025

GREATER CHINA Results Anta Sports (2020 HK/BUY/HK$101.60/Target: HK$114.20) 1H25: Results in line; lowers Anta brand target slightly, but maintains group-level target. CR Land (1109 HK/BUY/HK$30.40/Target: HK$34.10) 1H25: Results in line; positive 2H25 sales outlook & regular REIT expansion vision. Horizon Robotics (9660 HK/BUY/HK$7.94/Target: HK$8.88) 1H25: Hardware shipments more than double; eyeing mass pro...

Greater China Research Team
  • Greater China Research Team

Greater China Strategy Alpha Picks: August Conviction Calls

In July, the HSI and MSCI China index extended their growths, rising 2.9% mom and 4.5% mom respectively to reach their peak on 24 July before pulling pack in the latest week, as investors tend to take profit after the Politburo announcement. With another 90-day tariff delay from the US, we maintain a positive outlook for leading domestic stocks in healthcare and IT. New additions to our BUY list are JBM Healthcare and Lenovo. We take profit on CATL, Han’s Laser, KE Holdings and Longfor.

Audrey Celia ... (+16)
  • Audrey Celia
  • Bella Lu Yifei
  • Benjaphol Suthwanish
  • Carol Dou Xiao Qin
  • Greater China Research Team
  • Heidi Mo Jinghui
  • Jack Goh Tooan Orng
  • John Cheong Ming Chern
  • Jonathan Koh
  • Julia Pan Mengyao
  • Ken Lee
  • Kong Ho Meng
  • Ming San Soong
  • Sunny Chen
  • Tanapon Cholkadidamrongkul
  • Willinoy Sitorus

Regional Morning Meeting Notes: Thursday, July 31, 2025

GREATER CHINA Sector Healthcare Bi-Weekly: Expecting strong 1H25 results. Maintain OVERWEIGHT. Results Contemporary Amperex Technology (300750 CH/BUY/Rmb277.09 /Target: Rmb390.00) 2Q25: Earnings in line, with margins hitting record-high levels. Maintain A-share at BUY. Downgrade H-share to HOLD. New Oriental Education & Technology Group (EDU US/BUY/US$44.37/Target: US$55.00) ...

Benjaphol Suthwanish ... (+15)
  • Benjaphol Suthwanish
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Damon Shen
  • Desmond Chong Chee Wai
  • Ejann Hiew
  • Jieqi Liu
  • John Cheong Ming Chern
  • Posmarito Pakpahan
  • Shirley Wang Xueyi
  • Stella Guo Yuting
  • Sunny Chen
  • Tham Mun Hon
  • Thanawat Thangchadakorn
  • Wei Xiang Ku

Regional Morning Meeting Notes: Wednesday, July 16, 2025

GREATER CHINA Economics Economic Activity Resilient 1H25 growth of 5.3% yoy belies rising downside pressure. Sector Healthcare Weekly: Gaining strength on robust earnings outlook and pipeline growth. Maintain OVERWEIGHT. Property Property sales and prices weakened further in J...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Innovent Biologics (1801 HK): Becoming a significant player in the wei...

Mazdutide (the global first GCG/GLP-1 receptor agonist) recently received NMPA approval. Given Mazdutide’s early mover advantage, favourable clinical benefits and competitive pricing strategy, Innovent aims to become a significant player in the domestic weight management market. The effective commercial strategies and new wave of innovative product launches will continue to boost revenue and earnings growth from 2025 onwards for Innovent. Maintain BUY and target price of HK$110.00.

Adrian Loh Tzum Yung ... (+9)
  • Adrian Loh Tzum Yung
  • Alden Gabriel Lam
  • Carol Dou Xiao Qin
  • Chong Lee Len
  • Keith Wee Teck Keong
  • Paula Ruth
  • Sunny Chen
  • Tanapon Cholkadidamrongkul
  • Willinoy Sitorus

Regional Morning Meeting Notes: Monday, July 14, 2025

GREATER CHINA Update Innovent Biologics (1801 HK/BUY/HK$80.55/Target: HK$110.00) Becoming a significant player in the weight management market in China. INDONESIA Sector Automobile Weak Jun 25 sales; BYD recently increased prices. Update XLSMART Telecom Sejahtera (EXCL IJ/BUY/Rp2,230/Target: Rp2,600) Focusing on long-term benefits of positive synergies from the merger, upgrade to BUY. MALAYSIA Sector...

Carol Dou Xiao Qin ... (+3)
  • Carol Dou Xiao Qin
  • Greater China Research Team
  • Sunny Chen

Greater China Daily: Monday, July 14, 2025

KEY HIGHLIGHTS Update Innovent Biologics (1801 HK/BUY/HK$80.55/Target: HK$110.00) Mazdutide (the global first GCG/GLP-1 receptor agonist) recently received NMPA approval. Given Mazdutide’s early mover advantage, favourable clinical benefits and competitive pricing strategy, Innovent aims to become a significant player in the domestic weight management market. The effective commercial strategies and new wave of innovative product launches will continue to boost revenue and earnings growth from ...

Greater China Research Team
  • Greater China Research Team

Greater China Strategy: Alpha Picks -- July Conviction Calls

June’s HSI and MSCI China Index rose 3.4% mom and 4.0% mom respectively, despite the pullback due to the Middle East tensions. July may see increased volatility as the US looks to bring the tariff negotiations to a close. At this juncture, we continue to favour domestic policy beneficiaries and sector leaders. New additions to our BUY list are CATL, KE Holdings, Longfor, Midea Group, Tencent and Tencent Music Entertainment. We take profit on Prudential.

Regional Morning Meeting Notes: Thursday, July 03, 2025

GREATER CHINA Strategy Alpha Picks: July Conviction Calls Add CATL, KE Holdings, Longfor, Midea Group, Tencent and TME to our BUY list. Take profit on Prudential. Sector Online Games Upcoming new game releases to capitalise on the summer holiday season. INDONESIA Strategy Alpha Picks: Good Performances In June Our new alpha picks are ANTM, BBCA, ERAA, ICBP, MYOR, MIKA...

BJC BERLI JUCKER PUBLIC CO. LTD.
AEONTS AEON THANA SINSAP (THAILAND) PCL
CK CH. KARNCHANG PCL
KTC KRUNGTHAI CARD PCL
A0M4P7 HAN'S LASER TECHNOLOGY INDUSTRY GROUP CO. LTD. CLASS A
00291 CHINA RESOURCES BEER (HOLDINGS) CO. LTD.
ANTM PT ANEKA TAMBANG TBK
BN2 VALUETRONICS HOLDINGS
3K1 KINGSOFT CORP. LTD.
RLF LONGFOR GROUP HOLDINGS LTD.
AMRT SUMBER ALFARIA TRIJAYA TBK PT
AIY IFAST
COM7 COM7
558 UMS HOLDINGS LIMITED
MYOR MAYORA INDAH
C52 COMFORTDELGRO CORPORATION LIMITED
KBANK KASIKORNBANK PUBLIC CO. LTD.
01177 SINO BIOPHARMACEUTICAL LIMITED
BBCA PT BANK CENTRAL ASIA TBK
O39 OVERSEA-CHINESE BANKING CORPORATION LIMITED
002472 ZHEJIANG SHUANGHUAN DRIVELINE (A)
ERAA ERAJAYA SWASEMBADA
TLKM PT TELKOM INDONESIA (PERSERO) TBK CLASS B
000333 MIDEA GROUP CO. LTD. CLASS A
00700 TENCENT HOLDINGS LTD.
TCAP THANACHART CAPITAL PCL
MIKA MITRA KELUARGA KARYASEHAT
SAWAD SRISAWAD CORPORATION PUBLIC COMPANY LTD
D01 DAIRY FARM INTERNATIONAL HOLDINGS LIMITED
01810 XIAOMI CORP. CLASS B
VSI V.S. INDUSTRY BERHAD
MTC MUANGTHAI CAPITAL PCL
SSG SHENG SIONG GROUP LTD
ICBP INDOFOOD CBP SUKSES MAKMUR T
CPALL TB CP ALL
01801 INNOVENT BIOLOGICS INC.
PROP PROPNEX LTD
FEH FOOD EMPIRE HOLDINGS LTD
FRKN FRENCKEN GROUP LTD
CSSC CHINA SUNSINE CHEMICAL HOLDINGS LTD
09988 ALIBABA GROUP HOLDING LTD.
09999 NETEASE INC
CICT CAPITALAND INTEGRATED COMMERCIAL TRUST
LREIT SP LENDLEASE GLOBAL COMMERCIAL REIT
02618 JD LOGISTICS INC
02423 KE HOLDINGS INC.
CLAR CAPITALAND ASCENDAS REIT
SDG SD GUTHRIE BHD
STECON STECON GROUP PUBLIC COMPANY LIMITED
1698 HK TENCENT MUSIC ENTERTAINMENT GROUP
TIDLOR TIDLOR HOLDINGS PCL
3750 CONTEMPORARY AMPEREX TECHNOLOGY (3750 HK)
Claire Wang Kelai ... (+3)
  • Claire Wang Kelai
  • Greater China Research Team
  • Tham Mun Hon

Greater China 2H25 Market Strategy: A Big Beautiful Deal?

 Trade deal in focus. Notwithstanding the 90-day truce on tariff escalation, it is still a 50/50 if there will be a “Big Beautiful Deal” between the US and China. The US is steadfast in wanting to cap China’s growth and restricting her access to the latest technology, while China is making a firm stand on its economic rights. We expect that higher US tariffs on Chinese goods are unavoidable, likely closer to the 60% mark, if Trump were to be seen making a credible move to onshore production in ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare: Entering a new phase of accelerated growth. Upgrade ...

China's biotechnology sector has entered an accelerated growth phase, with firms expanding their innovative commercial product portfolios, achieving significant outlicensing deals and enjoying unexpected profitability. With an unprecedented showing of 74 oral presentations at ASCO 2025, the sector highlighted its robust pipeline and expanding role in global innovation. Sustained policy support and globalisation efforts will further support this expansion. Upgrade to OVERWEIGHT with Innovent, Han...

Carol Dou Xiao Qin ... (+12)
  • Carol Dou Xiao Qin
  • Gigi Cheuk
  • Heidi Mo Jinghui
  • Jack Lai Yuan Khai
  • John Cheong Ming Chern
  • Julia Pan Mengyao
  • Kate Luang
  • Lester Siew
  • Ming San Soong
  • Sunny Chen
  • Thanawat Thangchadakorn
  • Willinoy Sitorus

Regional Morning Meeting Notes: Thursday, June 19, 2025

GREATER CHINA Sector Healthcare Entering a new phase of accelerated growth. Upgrade to OVERWEIGHT. Internet 618 Festival – Evolving consumer trends and continued focus on value for money. Small/Mid Cap Highlights JBM Healthcare (2161 HK/BUY/HK$2.85/Target: HK$3.31) Takeaways from luncheon. INDONESIA Update Kalbe Farma (KL...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare: Entering a new phase of accelerated growth. Upgraded...

China's biotechnology sector has entered an accelerated growth phase, with firms expanding their innovative commercial product portfolios, achieving significant outlicensing deals and enjoying unexpected profitability. Moreover, Chinese biotech firms had an unprecedented showing at ASCO 2025, with 74 oral presentations highlighting their robust pipelines and the sector's strong growth trajectory. Sustained policy support and globalisation efforts will further support this expansion. Upgrade to O...

Greater China Research Team
  • Greater China Research Team

Greater China Strategy Alpha Picks: June Conviction Calls

The HSI and MSCI China index rebounded 5.3% mom and 3.5% mom respectively in May, after China and the US agreed on a 90-day tariff truce. Nonetheless, geopolitical uncertainties and tariff war risks remain. Hence, we continue to favour domestic policy beneficiaries and defensive sectors that have been gaining traction in recent weeks. New additions to our BUY list are Prudential and Sino Biopharm, and we take profit on SHKP and Trip.com.

Adrian Loh Tzum Yung ... (+9)
  • Adrian Loh Tzum Yung
  • Desmond Chong Chee Wai
  • Greater China Research Team
  • Kasemsun Koonnara
  • Kong Ho Meng
  • Malaysia Research Team
  • Roy Chen Chengzhi
  • Vincent Khoo Boo Aik
  • Willinoy Sitorus

Regional Morning Meeting Notes: Wednesday, June 04, 2025

GREATER CHINA Strategy Alpha Picks: June Conviction Calls Add Prudential and Sino Biopharm to our BUY list. Take profit on SHKP and TCOM. Update Qingdao Port International (6198 HK/NOT RATED/Price: HK$6.54) Key takeaways from NDR. INDONESIA Update Sumber Alfaria Trijaya (AMRT IJ/BUY/Rp2,620/Target: Rp3,000) Synergy potential from Lawson; expansion outside Java remains intact. MALAYSIA Strategy 1Q25 Results Wrap-Up ...

Greater China Research Team
  • Greater China Research Team

Greater China Alpha Picks: May Conviction Calls

The HSI and MSCI China index fell 4.3% mom and 5.2% mom respectively in April, driven by Trump’s tariff announcements in early-April and fears of a potential global recession. Due to the ongoing external uncertainties, we will maintain our exposure to domestic policy beneficiaries and defensive sectors. New additions to our BUY list are Alibaba, Innovent, Shuanghuan, and Trip.com, and we take profit of CR Land and JBM Healthcare.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch